#4859
Expert Nurse
Krista Rubin

Exciting news that encorafenib + binimetinib were FDA approved yesterday for metastatic melanoma with an identified BRAF v600E/K mutation. This combination has SIGNIFICANTLY less pyrexia than other regimens (notably D + T), and also has the added benefit if minimal photosensitivity over vemurafenib. For those patients intolerant of dabrafenib + trametinib due to pyrexia, they now have an opportunity to switch to enco/bini and hopefully, be able to stay on the meds.

One other advantage is both enco and bini can be taken with OR without food! That makes scheduling so much easier for patients.